Bernstein Upgrades Shire (SHPGY) to Outperform; Lifts Target to $65
More News related to SHPGY
- Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium
- Exane BNP Paribas Upgrades Biotechnology and Drugs Stocks SNY & SHPGY to Outperform
- Notable Analyst Rating Changes 01/20: KELYA, CBS, SHPGY, SWIR, IBM Upgraded; TSCO, BIG, AAP, VRS, CPO Downgraded
- J.P. Morgan Upgrades Shire plc (SHPGY) to Overweight
- Jefferies & Co Upgrades Shire plc (SHPGY) to Buy
More News related to Upgrades
- UBS Upgrades Commerce Bancshares (CBSH) to Buy; Valuation: Quality Deserves a Premium
- UBS Upgrades Cimarex (XEC) to Buy; Raises Estimates & PT on Positive Q4 Report
- Sidoti & Co Upgrades AMCOL International (ACO) to Buy
- Davenport Upgrades Foster Wheeler (FWLT) to Buy; Sell-off is Overdone
- Brean Murray Upgrades Iconix Brand Group (ICON) to Buy
Sanford C. Bernstein upgrades Shire plc (Nasdaq: SHPGY) from Market Perform to Outperform. The firm also raised its price target from $37 to $65.
Shares of Shire are trading about 1.4% higher today. With the stock most recently trading at $57.20, the firm's new price target represents potential upside of about 14%.
Visit our Analyst Ratings page to see all the upgrades/downgrades on shares of Shire.
Shire plc is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Related Categories
UpgradesStocks Mentioned
-0.58Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
